adMare BioInnovations welcomes Patricia Gauthier, President and General Manager of Moderna Canada, as the newest member of its Board of Directors. Patricia brings to adMare a wealth of leadership experience… Read More
Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in July 2022 LUPKYNIS is the first oral medicine approved in both the U.S…. Read More
Vancouver, BC – September 19, 2022 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results… Read More
CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 Crohn’s disease is a chronic, systemic disease that manifests as inflammation… Read More
Achieves development milestones required to complete Series A financing – Plans to file Phase 2 investigational new drug (IND) application by year end, with first patient dosing in Q1 2023… Read More
